Free Trial

Roth Capital Weighs in on Joint's Q1 Earnings (NASDAQ:JYNT)

Joint logo with Medical background

Key Points

  • Roth Capital has revised its Q1 2026 earnings estimate for Joint Corp. to $0.17 per share, an increase from the previous estimate of $0.14.
  • Joint reported a Q1 loss of ($0.06) EPS, surpassing analysts' expectations of ($0.07) and generating revenue of $13.27 million.
  • The company initiated a $5 million share buyback program, indicating that its board believes the stock is undervalued.
  • Looking to export and analyze Joint data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

The Joint Corp. (NASDAQ:JYNT - Free Report) - Analysts at Roth Capital lifted their Q1 2026 earnings per share estimates for Joint in a research report issued to clients and investors on Thursday, August 7th. Roth Capital analyst G. Kelly now expects that the company will earn $0.17 per share for the quarter, up from their prior estimate of $0.14. The consensus estimate for Joint's current full-year earnings is $0.11 per share. Roth Capital also issued estimates for Joint's Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.18 EPS and Q4 2026 earnings at $0.26 EPS.

JYNT has been the subject of a number of other research reports. B. Riley decreased their price objective on shares of Joint from $20.00 to $18.00 and set a "buy" rating for the company in a report on Friday. Lake Street Capital reduced their target price on shares of Joint from $20.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday, May 9th.

Check Out Our Latest Stock Report on JYNT

Joint Trading Up 2.6%

Shares of JYNT traded up $0.28 during trading hours on Monday, reaching $11.08. 48,519 shares of the company traded hands, compared to its average volume of 46,006. The stock's fifty day moving average price is $11.50 and its 200 day moving average price is $11.10. The firm has a market cap of $169.56 million, a price-to-earnings ratio of -33.58 and a beta of 1.53. Joint has a 12-month low of $9.58 and a 12-month high of $13.47.

Joint (NASDAQ:JYNT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. Joint had a positive return on equity of 0.67% and a negative net margin of 7.02%. The company had revenue of $13.27 million during the quarter, compared to analysts' expectations of $13.32 million.

Institutional Trading of Joint

A number of hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its position in Joint by 5,141.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,254 shares of the company's stock valued at $26,000 after acquiring an additional 2,211 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Joint by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 5,088 shares of the company's stock worth $54,000 after purchasing an additional 1,735 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Joint during the 1st quarter worth $88,000. JPMorgan Chase & Co. boosted its position in Joint by 32.3% during the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company's stock valued at $86,000 after purchasing an additional 1,810 shares in the last quarter. Finally, Sanders Morris Harris LLC purchased a new position in Joint in the second quarter valued at about $145,000. 76.88% of the stock is owned by hedge funds and other institutional investors.

Joint announced that its board has approved a stock buyback plan on Thursday, June 5th that permits the company to buyback $5.00 million in shares. This buyback authorization permits the company to purchase up to 2.7% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its stock is undervalued.

About Joint

(Get Free Report)

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Featured Stories

Earnings History and Estimates for Joint (NASDAQ:JYNT)

Should You Invest $1,000 in Joint Right Now?

Before you consider Joint, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Joint wasn't on the list.

While Joint currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines